Genomic diversity and antimicrobial resistance of *Prevotella* spp. isolated

from chronic lung disease airways

Kasey A. Webb^{1,2}, Olusola Olagoke^{1,2}, Timothy Baird^{2,3}, Jane Neill³, Amy Pham⁴, Timothy J. Wells⁴, Kay A. Ramsay^{5†}, Scott C. Bell^{5,6,7}, Derek S. Sarovich^{1,2*#}, and Erin P. Price^{1,2*#}

¹GeneCology Research Centre, University of the Sunshine Coast, Sippy Downs, QLD, Australia

²Sunshine Coast Health Institute, Birtinya, QLD, Australia

³Sunshine Coast Hospital and Health Service, Sunshine Coast University Hospital, Birtinya, QLD, Australia

⁴University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, QLD, Australia

⁵QIMR Berghofer Medical Research Institute, Herston, QLD, Australia

⁶Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Chermside, QLD, Australia

⁷Translational Research Institute, Woolloongabba, QLD, Australia

[†]Present address: Child Health Research Centre, The University of Queensland, Centre for Children's Health Research, South Brisbane, QLD, Australia

*Authors contributed equally to this work

[#]Corresponding authors

University of the Sunshine Coast, Locked Bag 4, Maroochydore DC, Qld, 4558, Australia

Email: dsarovich@usc.edu.au; Ph: +61 5456 3748

Email: eprice@usc.edu.au; Ph: +61 7 5456 5568

Key Words: *Prevotella*, genomics, cystic fibrosis, chronic obstructive pulmonary disease, respiratory infections, polymicrobial infections, real-time PCR, diagnostics, sputum

1 Data summary

- 2 Thirty-five Prevotella spp. genomes generated in this study are available in the Sequence Read
- 3 Archive (SRA) and GenBank databases under BioProject accession PRJNA742126.

4 Abstract

5 Cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) are characterised by 6 increasingly frequent acute pulmonary exacerbations that reduce life quality and length. Human 7 airways are home to a rich polymicrobial environment, including members of the obligately anaerobic 8 genus, Prevotella. Despite their commonness, surprisingly little is known about the prevalence, role, 9 genomic diversity, and antimicrobial resistance (AMR) potential of Prevotella species/strains in 10 healthy and diseased airways. Here, we used comparative genomics to develop a real-time PCR 11 assay to permit rapid Prevotella spp. quantification from cultures and clinical specimens. Assay 12 specificity was validated across a panel of Prevotella and non-Prevotella species, followed by PCR 13 screening of CF and COPD respiratory-derived cultures. Next, 35 PCR-positive isolates were 14 subjected to whole-genome sequencing. Of eight identified species, P. histicola, P. melaninogenica, 15 P. nanceiensis, P. salivae and P. denticola overlapped between participant cohorts. Phylogenomic 16 analysis revealed considerable interhost but limited intrahost diversity, suggesting patient-specific 17 lineages in the lower airways, probably from oral cavity aspirations. Correlation of phenotypic AMR 18 profiles with AMR gene presence identified excellent correlation between tetQ presence and 19 decreased doxycycline susceptibility, and ermF presence and decreased azithromycin susceptibility 20 and clindamycin resistance. AMR rates were higher in the CF isolates, reflecting greater antibiotic use 21 in this cohort. All tested Prevotella isolates were tobramycin-resistant, providing a potential selection 22 method to improve Prevotella culture retrieval rates. Our addition of 35 airway-derived Prevotella 23 genomes to public databases will enhance ongoing efforts to unravel the role of this diverse and 24 enigmatic genus in both chronic respiratory diseases and healthy lungs.

25 Introduction

26 Chronic lung diseases are a leading cause of global healthcare burden and early mortality^{1,2}. Although 27 cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) have fundamentally different 28 aetiologies, both are characterised by impaired airway mucociliary clearance, which provides a 29 favourable environment for microbial colonisation and persistence, and a challenging environment for 30 pathogen eradication. Infections are the primary contributor in CF and COPD respiratory 31 exacerbations (i.e. acute worsening of symptoms), during which inflammation and irreversible airway 32 damage can occur³. In CF, 80-95% of deaths are associated with acute exacerbations and chronic bacterial infections, which eventually lead to respiratory failure⁴. In COPD, bacterial, viral, and fungal 33 34 respiratory infections trigger ~70-80% exacerbation events⁵. Despite their crucial role in reducing 35 quality and length of life, there remain major gaps in understanding the collective microbial drivers 36 associated with CF and COPD pathophysiology. 37 Routine culture-based diagnosis of CF and COPD exacerbations often overlooks more fastidious or 38 uncultivable members within the airway microbiome, leaving a gap in fully understanding the complex composition and activity of CF and COPD microbiomes^{6,7}. Culture-independent techniques like 39 40 metataxonomics (e.g. 16S rRNA amplicon sequencing), metagenomics, and metatranscriptomics are 41 gaining traction as adjuncts or potentially even alternatives to culture due to their ability to identify a 42 much broader spectrum of microbes, including uncultured taxa, resulting in better diagnosis, more informed treatment strategies, and improved clinical outcomes⁸⁻¹⁰. In addition to identifying well-43 44 characterised microbes associated with respiratory exacerbations, molecular methods have unveiled 45 previously unidentified microbial communities in chronic lung disease airways, including a diverse anaerobic microbiome¹¹. 46 The Prevotella genus, which comprises ≥51 species^{12,13}, is a common and often abundant obligate 47 anaerobe in the human body, including in CF and COPD airways^{11,14-19}. Despite its commonness, the 48 role of *Prevotella* in disease progression is incompletely understood in CF¹¹, and even less so in 49 50 COPD. Several studies investigating *Prevotella* spp. in airway disease, particularly CF, have yielded

51 conflicting evidence. Some studies suggest a likely pathogenic role^{18,20}, whereas others have shown

52 no role²¹, or even a benefit when *Prevotella* spp. are abundant^{22,23}. A major contributor to these

53 equivocal findings is that culture-dependent and metaxonomic methods largely fail to identify

microbes to the species and strain level^{7,13,24,25}. As such, only a handful of *Prevotella* studies have 54 55 described potential species- or strain-specific mechanisms in airway disease pathogenesis. 56 The number of *Prevotella* genomes has been steadily increasing in recent years. However, in 57 comparison to more intensely studied CF and COPD airway organisms, there is a relative paucity of 58 respiratory Prevotella genomic data in public databases. Most Prevotella species contain only a single representative (and many were generated from a single metagenomic study)²⁶, leading to issues with 59 60 correct species assignments from metagenome-assembled genomes. Further, most genomic studies 61 have concentrated on known pathogens in oral (e.g. P. intermedia and P. nigrescens), gut (e.g. P. copri), and urogenital (e.g. P. bivia) microbiomes²⁷⁻²⁹. There is a lack of knowledge about the 62 63 Prevotella spp. commonly found in airways, particularly in COPD. Insufficient resolution to the species 64 and strain level has limited our understanding of Prevotella spp. diversity, function, evolution, and 65 antimicrobial resistance (AMR) potential within CF and COPD airways during exacerbations and stability^{13,24}. 66 67 Here, we first used a comparative genomics approach to design and optimise a novel real-time PCR 68 assay to permit the rapid, cost-effective, and specific detection of Prevotella spp. from both culture 69 and clinical specimens. Next, 43 CF-COPD sputa and bronchial washings were cultured to isolate 70 individual Prevotella strains for whole-genome sequencing (WGS) characterisation, followed by 71 genomic analyses to determine species identity, strain relatedness, and within-host evolution. 72 Cultured isolates were subject to AMR testing across 11 clinically-relevant antibiotics, and correlated 73 with AMR determinants identified by WGS. Finally, Prevotella morphological characteristics were 74 assessed for their diagnostic value.

75 Methods

76 Ethics statement. Collection and analysis of clinical samples was approved by The Prince Charles 77 Hospital (TPCH) Human Research Ethics Committee (HREC), project IDs HREC/13/QPCH/127 (CF 78 samples) and HREC/2019/QPCH/48013 (COPD samples). Site-specific approvals were obtained for 79 CF recruitment at TPCH, Brisbane, Australia, and COPD recruitment at Sunshine Coast Hospital and 80 Health Service, Sunshine Coast, Australia. All participants provided written consent. 81 Sample collection and storage. A total of 36 CF sputa were obtained from 21 expectorating adults 82 with CF presenting at TPCH Adult CF Centre between 2017 and 2019. Seven participants provided 83 multiple sequential sputa (Table S1). Sputa were stored non-anaerobically at -80°C in Luria-Bertani 84 broth containing 20% glycerol, and stored for 2-24 months prior to microbiological assessment. A total 85 of 32 COPD sputa (n=21) or bronchial washings (BWs; n=11) were obtained from 21 current/former

tobacco smokers during community or in-hospital consult at Sunshine Coast Hospital and Health

87 Service in 2020 (**Table S1**). Five participants provided multiple sequential sputa (**Table S1**). BWs

88 were taken from participants with suspected lung cancer, with most collected as paired specimens

89 from both the tumour site (biopsied after BW collection) and approximately the same position in the

90 non-tumour contralateral (contra) lung. BWs were pelleted at 4°C and ~9,300 x g for 15 min, with

supernatant removed and pellet resuspended in 800 µL phosphate-buffered saline. COPD samples

92 were stored within 12-36 hours of collection using the same parameters as described for the CF

93 specimens, and microbiologically processed within ~2 weeks of collection. Clinical and antibiotic

94 treatment regimens were recorded (**Table S1**) to permit correlation with *Prevotella* AMR profiles.

95 <u>Microbiological preparation and storage</u>. Clinical samples were directly subcultured onto anaerobic

96 blood medium containing nalidixic acid and vancomycin (Thermo Fisher Scientific, Seventeen Mile

97 Rocks, QLD, Australia; cat. no. PP2065). Plates were incubated anaerobically at 37°C in an

98 AnaeroPack 2.5L jar with an AnaeroGen 2.5L gas pack (Thermo Fisher) for 2-5 days. Isolates were

subcultured based on different morphotypes, with a second subculture for purity onto non-selective

anaerobic blood medium (Thermo Fisher; cat. no. PP2039). *Prevotella* real-time PCR-positive isolates

101 were again sub-cultured onto non-selective anaerobic blood medium for purity and stored non-

102 anaerobically at -80°C in 1mL Luria-Bertani broth containing 20% glycerol. Additionally, WGS-

103 confirmed, representative *Prevotella* isolates derived from CF samples were cultured from glycerol

104 stocks onto both polyvitaminic-supplemented chocolate agar (PVCA; Edwards Group, Murrarie, QLD,

Australia; cat. no. 1065) and non-selective anaerobic blood medium to assess phenotypic differences
over a 10-day period.

107 DNA extractions. DNA of presumptive Prevotella spp. isolates was initially extracted using 5% chelex-108 100³⁰ (Bio-Rad, Gladesville, NSW, Australia), heat-treated at 95°C for 20 min, and diluted to 1:50 with 109 molecular-grade H₂O prior to PCR. DNA for WGS was extracted using the Gram-positive bacteria 110 protocol of the DNeasy Blood and Tissue Kit (Qiagen, Chadstone, VIC, Australia). Qiagen extractions 111 were quality-checked and quantified using the NanoDrop 2000 spectrophotometer (Thermo Fisher). 112 Clinical specimens were extracted using 3 parts TRI Reagent LS (Sigma-Aldrich, North Ryde, NSW, 113 Australia) to 1 part specimen, 30µL 0.1M 2-mercaptoethanol, and ~ 100µL equal mixture of 0.1 and 114 0.5mm zirconia beads (Daintree Scientific, St Helens, TAS, Australia). Homogenisation comprised 115 eight rounds of 30 sec bead beating (each round followed by 30-60 sec on wet ice) using the 116 'medium' setting of the Minilys tissue homogeniser (Bertin Instruments, Montigny-le-Bretonneux, 117 France). After removal of the RNA aqueous phase, back extraction was performed on the interphase and proteinaceous phase³¹ to isolate total DNA. 118 119 Prevotella spp. real-time PCR assay design. Due to high levels of genetic variability among Prevotella spp., the highly conserved 16S-23S rRNA genes were targeted. A custom BLAST³² 2.10.2+ database 120

121 was created using 60 *Prevotella* spp. genomes encompassing 26 assigned and nine unassigned

122 species (Table S2). Discontiguous MegaBLAST was carried out against the 4.8kb *P. intermedia*

123 ATCC 25611 23S-16S rRNA locus (GenBank accession CP019300.1, coordinates 63001-67800)

124 using the custom BLAST database. BLAST .xml outputs were aligned and visualised using Geneious

125 Prime vR10. A highly conserved area within the Prevotella spp. 16S rRNA gene was assessed further

126 to identify potential PCR oligos, with conserved regions possessing several single nucleotide

127 polymorphisms (SNPs) in other microbes exploited during probe and primer design. Primers and

128 probes were initially assessed using Primer Express v3.0 (Applied Biosystems) to test melting

129 temperature (T_m) suitability in Black Hole Quencher format (primer $T_m=60^{\circ}$ C; probe $T_m=70^{\circ}$ C). All

130 candidate primers and probes were assessed for self- and hetero-dimer formation using Beacon

131 Designer (<u>http://www.premierbiosoft.com/qpcr/</u>), with oligo sequences requiring a ΔG value of >-4

132 kcal/mol. Candidate oligos were subsequently subjected to NCBI Microbial Nucleotide BLAST and

133 Nucleotide BLAST searches to confirm specificity for *Prevotella* spp.. As the 16S region is highly

134 conserved in all bacteria, the forward primer incorporated a penultimate mismatch to prevent non-

135 specific binding to closely related non-Prevotella taxa. Additionally, a BHQplus probe (CAL Fluor Gold 136 540-pdCApdUApdUpdCGApdCGGGGpgUGG-BHQ1; Biosearch Technologies, Petaluma, California, 137 USA) was included to enhance specificity and to permit assay use on clinical specimens. Forward (5'-138 TTCTCCAGtCCAGGATGTGtC-3') and reverse (5'-CGGGGGATAACAGGCTGATCC-3') primers were 139 manufactured by Macrogen Inc. (Geumcheon-gu, Seoul, South Korea), with lowercase nucleotides 140 representing intentional mismatches. 141 Real-time PCRs were carried out on a Bio-Rad CFX96 thermocycler using 0.35µM primers and probe, 142 1X Sso Advanced Universal mastermix (Bio-Rad), molecular-grade H2O, and 1µL template, to a 5µL

final volume. Thermocycling parameters were: 95°C for 2 min, followed by 45 cycles of 95°C for 5 sec

144 and 60°C for 20 sec. DNA integrity for all clinical samples was assessed via amplification towards β-

145 globin³³ (human) and universal 16S rRNA³⁴ (bacteria); the universal 16S rRNA assay was also used

to verify bacterial culture DNA integrity, and a panfungal assay (O. Olagoke and E. Price,

147 unpublished) was used to verify *Candida* spp. DNA integrity.

148 Real-time PCR assay optimisation and specificity testing. The final optimised real-time PCR assay

149 was assessed for accuracy by running against a diversity panel of six Prevotella spp. (one each of P.

150 copri, P. denticola, P. histicola, P. melaninogenica, P. nigrescens, and P. salivae), 1 human DNA

151 sample, and 40 non-Prevotella spp., with a focus on common respiratory tract microbes (n=1 unless

152 otherwise stated): Achromobacter xylosoxidans, Bordetella bronchiseptica, Burkholderia cepacia,

153 Burkholderia territorii, Burkholderia thailandensis, Candida albicans, Candida dubliniensis,

154 Cupriavidus metallidurans, Enterobacter aerogenes, Enterobacter cloacae (n=3), Enterococcus

155 raffinosus, Klebsiella oxytoca, Klebsiella pneumoniae (n=2), Lacticaseibacillus paracasei (n=2),

156 Pseudomonas aeruginosa (n=12), Staphylococcus aureus (n=3), Staphylococcus haemolyticus,

157 Stenotrophomonas maltophilia, Veillonella atypica (n=3), Veillonella parvula, and Veilonella dispar. All

158 DNA was normalised spectrophotometrically to 2ng/µL prior to PCR.

159 Limits of detection (LoD) and quantification (LoQ) for the optimised assay were determined using P.

160 *melaninogenica* LMG 28911 DNA, using serial dilutions of $4ng/\mu L$ to $4 \times 10^{-6} ng/\mu L$ across 8 replicates

161 per dilution. The upper and lower LoD/LoQ limits were determined as described elsewhere³⁵. Genome

162 equivalence was determined based on an average *Prevotella* genome size of 3.29Mbp and a single

163 copy of the 16S rRNA gene.

<u>16S rRNA gene diversity profiling (metataxonomics)</u>. Metataxonomics was performed by the
 Australian Genome Research Facility (AGRF; Melbourne, VIC, Australia) for total CF DNA and ID
 Genomics (Seattle, WA, USA) for total COPD DNA using standard protocols for V3-V4 (i.e. 341F and
 806R) primers.
 Antimicrobial resistance (AMR) profiling. Twenty-eight glycerol-stocked *Prevotella* cultures were

169 subcultured onto non-selective anaerobic blood medium, or PVCA where no growth was obtained on

the anaerobic medium (*n*=2), and incubated at 37°C under anaerobic conditions for 2-3 days. Cultures

171 were then resuspended into phosphate-buffered saline to OD₆₀₀=0.75 (Biochrom, Cambridge, UK).

172 Six supplemented chocolate plates per isolate were lawn-inoculated with the OD-normalised cells as

173 previously described³⁶, and antibiotic discs (Edwards Group) towards 11 antibiotics (amoxicillin-

174 clavulanate [AMC] 30µg; azithromycin [AZM] 15ug; ceftazidime [CAZ] 30µg; chloramphenicol [CHL]

175 30µg; clindamycin [CLI] 2µg; doxycycline [DOX] 30µg; imipenem [IPM] 30µg; meropenem [MEM]

176 10µg; metronidazole [MZ] 5µg; piperacillin-tazobactam [TZP] P:100µg, TZ:10µg; tobramycin [TOB]

177 10µg) were placed onto inoculated plates. Plates were incubated at 37°C under anaerobic conditions

178 for 48h prior to measurement. As no disc diffusion reference ranges exist for *Prevotella* spp., growth

179 up to the disc (i.e. 6mm diameter) was denoted as AMR, which underestimates the true rate of AMR

180 but provides a clear cut-off for unambiguous interpretation. Diameters ≤30mm for any antibiotic were

181 denoted as reduced susceptibility.

182 <u>Whole-Genome Sequencing (WGS)</u>. PCR-confirmed *Prevotella* isolates were sequenced using the

183 Illumina HiSeq 2500 platform with 150bp seqWell plexWell paired-end read chemistry at AGRF.

184 <u>Genome assemblies</u>. Prevotella genomes were de novo assembled using default Microbial Genome

185 Assembly Pipeline v1.1 parameters (<u>https://github.com/dsarov/MGAP---Microbial-Genome-</u>

186 <u>Assembler-Pipeline</u>) or SPAdes³⁷.

187 <u>Speciation and mixture analysis</u>. *Prevotella* spp. assemblies were initially assessed for species

188 identification and mixtures using the Ribosomal MLST³⁸ tool. Isolates containing mixtures of

189 *Prevotella* and non-*Prevotella* species (*n*=8), or multiple *Prevotella* species (*n*=1) (**Table S3**), were

190 excluded from further investigation.

Phylogenetic analysis. A custom BLAST database of *Prevotella* genomes (*n*=234) comprising taxa of
 known (*n*=56) and unassigned (*n*=40) species, and including non-mixed isolate genomes sequenced

in this study (n=35 genomes), was created using BLAST 2.10.2+. BLAST analysis was performed 194 against the full-length 1,534bp P. melaninogenica 16S rRNA gene (RefSeq ID: NC_014371.1; bases 195 962,784-964,317). Hits were filtered to remove redundancies (final n=199), and reads aligned using 196 ClustalX2 v2.1³⁹. A dendogram was constructed using the neighbour-joining method and the Tamura-197 Nei model and viewed in FigTree v1.4.0 (http://tree.bio.ed.ac.uk/software/figtree/) using midpoint 198 rooting. 199 Phylogenomics. Variant identification of our CF-COPD genomes ('SCHI' prefix) was performed using SPANDx v4.0⁴⁰. Reference genomes for *P. denticola*, *P. histicola*, *P. melaninogenica*, *P. nanceiensis*, 200 201 and P. salivae were downloaded from GenBank (IDs GCA_000193395.1, GCA_000234055.1, 202 GCA 000144405.1, GCA 000163055.2, and GCA 000477535.1, respectively) and used for read

203 mapping. Synthetic reads were generated from GenBank genome assemblies for P. denticola

204 (GCA_000191765.2, GCA_000759205.1, GCA_000421205.1, GCA_003515045.1, and

205 GCA 900454835.1), P. histicola (GCA 000613925.1), P. melaninogenica (GCA 000163035.1,

206 GCA_000759305.1, GCA_002208725.2, GCA_003609775.1, and GCF_000517825.1), P.

207 nanceiensis (GCA_000517825.1 and GCA_000613985.1), and P. salivae (GCA_000185845.1 and

GCA 902374235.1) using ART v2.3.741. 208

193

209 Illumina reads for P. histicola T05-04T (SRR1518629) and P. nanceiensis ADL-403 (SRR755359)

210 were downloaded from the Sequence Read Archive database and quality filtered using Trimmomatic

211 v0.39⁴² parameters described elsewhere⁴³. The resulting biallelic, orthologous SNP matrix generated

212 by SPANDx was phylogenetically reconstructed using the maximum parsimony heuristic function of

213 PAUP* v4.0a (build 168). Phylogenies were visualised in FigTree; all trees were midpoint-rooted.

214 AMR determinant analysis. The Resistance Gene Identifier v5.1.1, which employs the Comprehensive

Antibiotic Resistance Database (CARD) v3.1.0⁴⁴, was used to identify putative AMR determinants. 215

216 Results and Discussion

217 Molecular typing approaches have been instrumental in unveiling previously untapped microbial 218 diversity in both healthy and diseased lungs. Using these techniques, Prevotella spp. have consistently been identified as one of the most prevalent taxa in CF and COPD airways^{10,14,19}. 219 220 However, most studies to date have employed 16S metataxonomics (usually targeting the V3-V4 221 gene region), which only characterises Prevotella to the genus level, despite species and strain 222 resolution being fundamental to unravelling the role of these anaerobes in chronic lung disease. To 223 address this knowledge gap, our study used a combination of culture-dependent and -independent 224 methods to examine the genomic and phenotypic diversity, and prevalence, of Prevotella spp. present 225 in CF and COPD airways.

226 We first used a comparative genomics-guided approach to develop an accurate real-time PCR assay 227 to enable the rapid detection of *Prevotella* spp., to the exclusion of all other organisms, both from 228 cultures and clinical specimens. Our PCR assay was reasonably sensitive, with LoD and LoQ both 229 being 400fg/µL, or 111 genome equivalents (Figure 1). When tested against a diverse panel of 47 230 microbial and human DNA, the PCR demonstrated 100% specificity, amplifying all six tested 231 Prevotella species, but none of the non-Prevotella spp. DNA and 10 no-template controls. On clinical 232 specimens, the PCR identified Prevotella in 81% CF and 71% COPD participants, and in 81% CF and 233 66% COPD specimens (Table 1). This difference in detection rates between diseases was expected 234 given the generally lower total bacterial load in COPD airways¹. Metataxonomics had higher 235 Prevotella sensitivity than PCR, identifying Prevotella in six PCR-negative samples, although there 236 was one false-negative (SCHI0049.C.3, which was PCR- and culture-positive); there was otherwise 237 near-perfect correlation between PCR and metataxonomics (Table S3). In the six PCR-negative 238 samples, Prevotella relative abundance was very low (0.004-0.3%; median=0.05%), indicating that 239 DNA levels were below the PCR LoD threshold. Thus, culture-independent methods are highly 240 suitable for accurate Prevotella spp. detection from polymicrobial specimens, particularly real-time 241 PCR, which is often performed upon clinical sample receipt, thereby permitting same-day detection of 242 *Prevotella* in respiratory samples.

Culture of sputa and BWs onto three different agars (anaerobic blood medium containing nalidixic
 acid and vancomycin, non-selective anaerobic blood medium, and PVCA) yielded a much lower
 Prevotella positivity rate compared with PCR and metataxonomics. Only 44% CF and 28% COPD

246 clinical specimens, respectively, were *Prevotella*-positive via culture, compared with 81% and 66% 247 using PCR, and 84% and 91% using metataxonomics (Table 1). The reduced retrieval rate in COPD 248 vs. CF can be explained by lower relative Prevotella abundance according to metataxonomics (0.3-249 74.3% [median=9.6%) for CF vs. 0.002%-36.4% [median=0.6%] for COPD). The lower prevalence of 250 Prevotella using culture is likely due to multiple factors, such as an inability of culture-independent 251 methods to distinguish viable from non-viable cells, nutritional fastidiousness, cells being in a viable 252 but non-culturable state, and outcompetition from faster-growing taxa^{9,19,22}. A prior study found that 253 four different culture media were required to recover 42 Prevotella isolates from 26 samples, and only 20 isolates were recoverable on more than one medium¹⁹. Moreover, all four media were required to 254 recover *P. melaninogenica* from all sputum samples¹⁹, suggesting that growth requirements may be 255 256 species- and strain-specific. In contrast to this prior work, we used aerobic collection and storage conditions, which likely precluded recovery of *Prevotella* taxa with poor/no aerotolerance⁴⁵. Consistent 257 258 with their fastidiousness, one P. histicola and five P. melaninogenica initially isolated in our study 259 were unable to be resuscitated from glycerol stocks upon repeated attempts, despite previously being 260 culturable. Taken together, it is probable that several Prevotella species or strains were not recovered 261 by culture in our study due to multiple factors, thereby underestimating species and strain diversity 262 within our cohorts.

263 To gain greater insight into Prevotella residing in CF and COPD airways, we performed WGS and 264 phylogenetic analysis on cultured isolates to determine species identity and strain relatedness. From 265 36 CF sputa, 27 PCR-positive Prevotella colonies were retrieved, of which 18 were Prevotella spp.; 266 the remaining nine contained a mixture of *Prevotella* and other taxa, or a mixture of multiple 267 Prevotella spp., due to insufficient subculturing for purity prior to WGS (Table S3). To avoid known 268 bioinformatic analysis issues associated with variant calling from mixtures⁴⁶, these mixed data were 269 excluded from phylogenetic analysis. Among the 18 isolates, WGS identified seven Prevotella spp.: P. 270 histicola (n=5), P. melaninogenica (n=5), P. denticola (n=3), P. nanceiensis (n=2), P. jejuni (n=1), P. 271 nigrescens (n=1), and P. salivae (n=1). Of the 17 COPD-derived isolates, none were mixed due to a 272 greater number of passages carried out to obtain purity. WGS identified six Prevotella spp.: P. 273 melaninogenica (n=8), P. histicola (n=3), P. salivae (n=3), P. buccae (n=1), P. denticola (n=1), and P. 274 nanceiensis (n=1) (**Table S3**). Despite being fundamentally different diseases, there was little 275 difference in Prevotella species found in CF and COPD, with only P. jejuni and P. nigrescens being

276 unique to CF, and P. buccae being unique to COPD. One explanation for this overlap is that the oral cavity and oropharynx are common habitats for all retrieved species, except P. jejuni⁴⁷; it is thus 277 278 possible that some strains we isolated were upper airway residents. Whilst oral cavity contamination 279 is unavoidable during respiratory secretion collection, especially for sputum, microbes can also enter 280 lower airways via small-volume oral cavity aspirations; indeed, the risk of microbial colonisation and persistence is greatly increased in mucociliary-impaired CF and COPD airways^{24,48-52}. In support of 281 282 lower airway origin, we identified Prevotella spp. in both sputa and BWs. Unlike sputa, BWs are 283 collected via bronchoscopy and thus far less prone to oral/oropharynx contamination, providing 284 greater confidence that many of our retrieved Prevotella isolates originated from the lower airways. 285 The origin of *P. jejuni* in one CF participant is somewhat perplexing. This species was first documented in the small intestine of a child with coeliac disease in 2012⁵³, and little is currently 286 287 known about the distribution of this organism in healthy and diseased niches. One possibility is that P. 288 jejuni entered the CF airways via inhalation of gastroesophageal aspirations. Alternatively, microbial 289 inter-compartment cross-talk between the lungs and gut (the 'Gut-Lung axis') via the mesenteric lymphatic system may explain its presence in the lungs⁵⁴. As a relatively new taxon, little is known 290 291 about possible mechanisms of P. jejuni pathogenesis, with more work needed to determine the 292 prevalence and virulence potential of this bacterium in both healthy and diseased airways. 293 The most frequently isolated species in our study - P. melaninogenica (37%), P. histicola (23%), P. 294 salivae (11%), P. denticola (11%), and P. nanceiensis (9%) - are common in CF^{14,15,19} and COPD²⁵ 295 airways. However, their precise role in airway disease is poorly understood due to conflicting reports 296 about their beneficial vs. pathogenic potential. For instance, P. melaninogenica, P. salivae, and P. 297 nanceiensis may inhibit non-typeable Haemophilus influenzae-induced pro-inflammatory cytokine production by lung dendritic cells⁵², increased *P. melaninogenica* prevalence in CF airways has been 298 299 associated with improved lung function¹⁵, and *P. histicola* can mute pro-inflammatory pathways triggered by *P. aeruginosa* in CF airways⁵⁵. In contrast, *P. melaninogenica* produced the greatest 300 301 variety of short-chain fatty acids (associated with inflammation) amongst five tested anaerobes¹⁸, and 302 P. denticola shares similarities in its lipid A moieties to P. intermedia (a known pathogenic species), pointing towards pro-inflammatory traits⁵⁶. Finally, certain strains of the periodontal disease-303 304 associated species, P. nigrescens, a close relative of P. intermedia, are thought to encode an 305 enzymatic cell hydrolysis mechanism that destroys tissues. Given the reported conflicting roles of

306 *Prevotella* spp. in chronic lung disease, these collective results suggest that virulence mechanisms
 307 vary among *Prevotella* strains, which requires further exploration^{57,58}. Our genomic data will assist
 308 these future efforts.

309 In our experience, metagenomic analysis tools can struggle with *Prevotella* species-level identification

310 from respiratory specimens due to a lack of accurate representative species in public databases.

311 Exemplifying this problem, few publicly available genomic data are available for *P. nanceiensis* – only

three were available at the time this study was undertaken, one of which is misclassified as *P*.

313 melaninogenica, and another as Prevotella sp. (Figure 3). Thus, our addition of three P. nanceiensis

314 genomes doubles the available P. nanceiensis data. Similarly, there are currently only a handful of

315 nonredundant *P. jejuni* genomes in public databases, and none are from lower airway specimens; our

addition *P. jejuni* SCHI0011.S.13 genome is therefore valuable for future respiratory and

317 gastroenterological studies. Taken together, our P. nanceiensis and P. jejuni genomes will help public

318 database curation efforts, and in turn, improve species identification using metagenomics.

319 To determine strain relatedness within and between participant airways, we undertook within-species

320 analyses of our P. denticola, P. histicola, P. melaninogenica, P. nanceiensis and P. salivae genomes

321 (Figure 3). Whole-genome SNP analysis revealed high levels of strain and interhost diversity in all

322 examined Prevotella species. For example, genetic variation was as high as ~72k SNPs among P.

323 *histicola* strains, an impressive feat for an organism encoding a 3Mbp genome, and *P. nanceiensis*

324 strains SCHI0010.S.3 and SCHI0011.S.12 were more closely related to strains isolated from France

325 and the US, respectively, than to other strains retrieved from other Australian participants. In contrast,

326 intrahost diversity was relatively limited (0-297 SNPs), with two instances of genetically

327 indistinguishable strains: P. histicola SCHI0034.S.5 and SCHI0034.S.6, and P. melaninogenica

328 SCHI0034.S.7 and SCHI0034.S.9 (Figure 3); the latter pair were retrieved from a BW and sputum

329 collected on the same day (Table S1; Table S3). The only exception was *P. melaninogenica* from

330 SCHI0027, where two genetically distinct lineages separated by >20k SNPs were retrieved from this

331 participant. There was no evidence of genetically-related strains between any of the Australian

332 participants for any *Prevotella* spp. (Figure 3). These findings indicate that interhost diversity is very

333 high, whereas within-host Prevotella diversity is limited, possibly due to frequent microaspiration of

334 *Prevotella* from upper to lower airways (or via the gut-lung axis) rather than chronic infection;

335 however, more in-depth sampling is required to investigate *Prevotella* persistence.

336 Antibiotics are routinely used in the maintenance and treatment of acute respiratory infections in CF and COPD^{15,59}. Given its uncertain pathogenic role, *Prevotella* spp. are not targeted by these 337 338 treatment regimens⁶⁰. Despite this, AMR rates in *Prevotella* are trending upwards⁵⁹, possibly due to 339 bystander selection. To examine this phenomenon, we determined AMR profiles for all culturable 340 Prevotella strains (n=27) using disc diffusion against 11 antibiotics commonly used to treat lung infections^{15,59}, or which have known activity against anaerobic taxa⁴⁷. AMR (AZM, CAZ, CLI, MZ, 341 342 TOB) or reduced susceptibility (AMC, AZM, CAZ, DOX, MEM) was observed in at least one strain, 343 whereas all were susceptible towards CHL, TZP, and IPM, an observation supported by previous studies^{47,59,61}. Reflecting much greater lifetime antimicrobial use in the CF cohort⁶², the 18 tested CF 344 345 strains had much higher AMR incidence (57% vs. 8%) and AMR gene presence (83% vs. 35%) 346 compared with COPD strains, and this rate increased to 100% (69% for COPD) when including 347 strains with reduced susceptibility towards one or more antibiotics (Table 2). In addition, almost all CF 348 participants were undergoing antimicrobial treatment with at least two different antibiotic classes at 349 the time of sample collection, vs. almost no antibiotic use in the COPD participants (Table S1). One 350 strain, CF isolate P. histicola SCHI0009.S.6, could be classed as multidrug-resistant due to exhibiting AMR towards three antibiotic classes⁶³ – β -lactams, lincosamides, and imidazoles – along with 351 352 reduced susceptibility towards the tetracycline-class antibiotic, DOX (Table 2). Our findings confirm 353 bystander AMR selection in off-target Prevotella as a direct result of heavy antimicrobial use in CF 354 (and to a much lesser extent, COPD), which may have ramifications for Prevotella persistence as a 355 potential driver of disease pathogenesis. 356 TOB was the only antibiotic tested that showed AMR in all tested isolates, including the type strain, P. 357 melaninogenica LMG 28911 (Table 2). This finding that concurs with prior work reporting 100% TOB

resistance among 157 *Prevotella* isolates⁵⁹. A CF microbiome study also found that *Prevotella*

abundance was largely unchanged upon TOB treatment⁶⁴. These collective findings indicate that all

360 respiratory *Prevotella* species are intrinsically resistant to TOB. Notably, we observed that the median

- 361 relative *Prevotella* abundance according to metataxonomics was quite different between CF (9.6%)
- 362 vs. COPD (0.6%) specimens (Table S3). Although the basis of this higher relative *Prevotella*

363 abundance in CF is unknown, one possibility is that most of our CF participants were receiving TOB

at the time of sample collection (Table S1; Table 2), whereas no COPD participant was receiving this

365 antibiotic. The predominance of *Prevotella* spp. in the CF airways might thus be attributed to much

more frequent TOB use in this cohort⁶⁵⁻⁶⁷. Although not assessed in this study, adding TOB to
selective media may improve *Prevotella* recovery rates from respiratory specimens by suppressing
growth of other taxa. After TOB, CLI resistance was most common (6/14 CF isolates), followed by
AZM (4/14 CF isolates), MZ (1/13 COPD and 3/14 CF isolates), and CAZ (2/14 CF isolates).
Decreased susceptibility towards AMC, CAZ, and DOX was common in both CF and COPD isolates;
however, only CF isolates exhibited decreased AZM susceptibility (6/14 isolates). These results

373 in CF-derived isolates.

374 AMR genes represent a major concern in infection control as these genes can rapidly transfer AMR 375 among different genera and species. To determine AMR gene potential, CARD analysis was 376 performed on the 35 CF-COPD Prevotella genomes and used to correlate horizontally acquired AMR-377 conferring genes with AMR/decreased susceptibility phenotypes. Consistent with their higher AMR 378 rates, CF isolates demonstrated greater prevalence of AMR-conferring genes compared with COPD 379 (Table 2). Strikingly, 67% CF strains encoded *ermF*, a horizontally-acquired gene that confers 380 resistance towards macrolide, lincosamide, and streptogramin-class antibiotics such as AZM and CLI^{47,61,68}. In contrast, *ermF* was absent in all COPD strains, a somewhat unexpected finding given 381 382 that COPD participants are frequently given long-term macrolides (e.g. azithromycin, erythromycin) as prophylaxis to reduce exacerbation frequency⁶⁹. None of the CF or COPD participants were receiving 383 384 these antibiotics at the time of sample collection, suggesting that cross-resistance or prior CF 385 antibiotic treatment may be driving *ermF* acquisition and maintenance in *Prevotella*. *ermF* presence 386 correlated well with AZM and CLI AMR/decreased susceptibility (87% and 75%, respectively). ermF 387 rates in our Australian isolates exceed those previously reported (23-68% in UK, USA, and Italian isolates from both healthy and diseased participants)^{68,70}. This discrepancy is likely due to only 388 389 respiratory disease-associated isolates being tested in our study, but may also be due to differences 390 in AMR cut-offs between studies, in vivo antibiotic exposure levels, and potentially species or strain 391 composition, noting that one study only identified most isolates to the genus level⁶⁸. tetQ, which confers resistance to tetracycline-class antibiotics (e.g. DOX)^{68,70}, was present in 54% of 392

393 our strains, and more common in CF-derived strains (67% vs. 41%). This rate is much higher than 394 tetQ prevalence reported in UK CF (21%)⁶⁸ and human-derived Dutch (30%)⁶¹ strains. Our tetQ-

harbouring strains consistently showed much smaller DOX disc diameters (12-30mm; median 22mm)

396 compared with tetQ-negative strains (40-64mm; median 54mm) with 100% correlation between tetQ 397 presence and decreased DOX susceptibility (Table 2). A prior study reported that 83% of tetQ-398 positive isolates demonstrated intermediate or full resistance towards tetracycline⁶⁸, suggesting that 399 tetQ is a reliable marker of reduced susceptibility towards tetracycline-class antibiotics. Taken 400 together, these results confirm that tetQ presence robustly confers decreased DOX susceptibility in 401 Prevotella spp. Although our dataset is small, we propose Prevotella spp. DOX disc diameters of 402 \geq 40mm to denote strains lacking tetQ, and \leq 30mm to denote strains that may be harbouring tetQ, with 403 the caveat that other enigmatic determinants conferring reduced DOX susceptibility (e.g. 404 chromosomal mutations) may be present in lieu of tetQ. These criteria also differentiate Prevotella 405 spp. exhibiting decreased DOX susceptibility from DOX-sensitive strains. The *cfxA*-type β-lactamase gene is the most clinically important AMR mechanism in *Prevotella* spp.⁷¹ 406 as it confers AMR towards cephamycins⁶¹ and some other β-lactam antibiotics⁶⁸, which are commonly 407 used in respiratory infection treatment⁵⁹. Concerningly, *cfxA* is often encoded on mobile elements, 408 409 meaning that AMR can potentially be transmitted from *Prevotella* spp. to known pathogenic taxa in the respiratory microbiome⁷². We found cfxA alleles 2, 3, 4, and/or 5 in 54% strains (72% CF and 35% 410 411 COPD). cfxA3 and cfxA2 were most common, being present in 37% and 14% strains, respectively. In 412 comparison, a study of UK and US isolates reported much higher cfxA carriage rates (86%), with 29% 413 and 52% strains encoding cfxA3 and cfxA2, respectively. Their study also found that cfxA3-encoding isolates exhibited significantly higher CAZ resistance levels⁶⁸, which we also observed in our *cfxA*3-414 415 harbouring strains (median disc diameter=12mm vs. 32mm in non-cfxA3 strains) (Table 2). In cfxA3encoding strains displaying CAZ sensitivity, reduced *cfxA3* expression⁷³ may explain this phenotype, 416 417 although this was not explored in our study. In addition, we did not test Prevotella susceptibility 418 towards cephamycins so were unable to determine whether cfxA variants correlated with these β-419 lactam antibiotics. 420 MZ resistance was evident in 4/28 tested strains (3 CF; 1 COPD), despite none of the participants 421 receiving nitroimidazoles at the time of sample collection. Other than TOB, MZ was the only antibiotic 422 that exhibited AMR in any of the COPD strains. The *nim* genes, which encode for nitroimidazole reductase enzymes and have previously been associated with MZ resistance in *P. baroniae*⁷⁴ and *P.* 423

*bivia*⁷⁵, were not detected in any isolate. Therefore, the basis of MZ resistance in our isolates remains

425 unknown.

426 Of the eight species identified in our study, four are conventionally considered dark-pigmented -P. 427 denticola, P. histicola, P. melaninogenica, and P. nigrescens. Pigmented Prevotella reportedly 428 harbour a greater cache of virulence factors and are more commonly associated with infection⁴⁷. 429 However, we found limited phenotypic differences within and between species on non-selective 430 anaerobic blood medium at Day 3 (Figure 4), with most presenting as convex, shiny, white colonies; 431 only *P. nigrescens* demonstrated tan pigmentation in the primary streak at this time point (Figure 4F). 432 In contrast, a dark brown to black pigment was produced by P. nigrescens on PVCA by Day 3 (Figure 433 5D), but not on selective or non-selective anaerobic media, even by Day 10, with only medium-brown 434 colonies present (Figure 5B and 5C). P. histicola demonstrated tan-coloured pigmentation on both 435 non-selective anaerobic medium and PVCA, but only after five days (Figure 6), and unlike P. 436 nigrescens, did not develop black pigment on PVCA at Days 5 or 10. P. melaninogenica reportedly produces a characteristic dark pigment that is commonly associated with the species^{76,77}; yet, no 437 438 pigmentation was observed in the six P. melaninogenica isolates on any medium by Day 10. A likely 439 explanation for this phenomenon is that different strains require different media for pigment 440 production⁷⁸. Collectively, the limited pigmentation observed among *Prevotella* spp. suggests that 441 phenotypic characteristics alone should not be used for Prevotella genus or species identification. 442 We acknowledge several study limitations. First, small sample size (43 enrolled participants; 69 443 samples) and inclusion of only COPD and CF samples makes it difficult to generalise our results 444 across a larger cohorts. Nevertheless, the broad agreement of our findings with previous literature^{10,14,19} demonstrates a reasonable estimation of species diversity in these cohorts. Second, 445 446 due to non-anaerobic sample handling and storage, non-aerotolerant Prevotella species may have 447 been rendered non-viable and thus not recoverable⁴⁵. Future establishment of disc diffusion 448 guidelines in *Prevotella* will enable more accurate assessment of AMR phenotypes in this genus. 449 Third, due to our use of a strict AMR cut-off (i.e. 6mm), AMR rates in our Prevotella are almost 450 certainly underestimated. Fourth, we did not assess healthy airway microbiota due to difficulties 451 associated with obtaining respiratory secretions from healthy participants. Future work should 452 continue to seek strain-level resolution of *Prevotella* strains in CF and COPD airways, including the 453 design of species-specific assays towards commonly isolated and known pathogenic species, 454 assessment of Prevotella from healthy airways, and incorporation of higher-resolution molecular 455 technologies such as metagenomics and metatranscriptomics to gain a clearer understanding of

- 456 Prevotella function within complex microbiomes. Co-culture experiments between Prevotella species
- 457 and known respiratory pathogens, such as *P. aeruginosa*, would be beneficial for elucidating the role
- 458 of Prevotella in potentiating or abrogating pathogen virulence. Finally, phylogeographic analysis of
- 459 Prevotella genomes may permit a deeper understanding of Prevotella spp. distribution and strain
- 460 diversity in chronic lung disease globally, and population genomic approaches will yield a better
- 461 understanding of *Prevotella* origin and capacity for airway-to-airway transmission.

462 Acknowledgements

- 463 We thank Tamieka Fraser (University of the Sunshine Coast) for laboratory assistance, Peter Timms
- 464 (University of the Sunshine Coast) and Laura Sherrard (Queen's University Belfast) for insightful
- 465 feedback on this manuscript, Tania Duarte (University of Queensland) for helpful discussions about
- 466 the challenges of *Prevotella* identification using current metagenomic pipelines, and the Belgian Co-
- 467 ordinated Collection of Micro-organisms (BCCM) for providing type strains. This work was funded by
- 468 Advance Queensland (awards AQRF13016-17RD2 and AQIRF0362018), the Wishlist Sunshine
- 469 Coast Hospital Foundation (award 2019-24), and the University of the Sunshine Coast.

470 Figure legends

- 472 **Figure 1**. Limits of detection (LoD) and quantification (LoQ) for the *Prevotella* real-time PCR assay.
- 473 The LoQ and LoD were both 400fg/µL according to previously defined parameters³⁵, or 111 genome
- 474 equivalents.
- 475 Figure 2. Full-length 16S ribosomal RNA gene phylogenetic analysis of the 35 Prevotella strains
- 476 retrieved in this study (identified by 'SCHI' prefix) against 199 non-redundant public Prevotella
- 477 genomes comprising 56 taxa of known species and 40 taxa of unassigned species. Species clades
- 478 containing isolates identified from our cystic fibrosis (CF) and chronic obstructive pulmonary disease
- 479 (COPD) specimens are coloured.
- 480 Figure 3. Maximum parsimony within-species phylogenomic reconstruction of *P. denticola*, *P.*
- 481 histicola, P. melaninogenica, P. nanceiensis and P. salivae. Strains identified from COPD and CF
- 482 specimens from this study are labelled with the 'SCHI' prefix; the remaining strains are public
- 483 genomes. The number of SNPs separating each strain is labelled on branches; where two or more
- 484 strains were retrieved from a single participant, coloured branch labels represent the number of SNPs
- separating these strains. CI, consistency index. Incorrectly speciated public genomes are denoted byan asterisk.
- 487 Figure 4. Three-day growth of *Prevotella* spp. on non-selective anaerobic blood medium. (A) P.
- 488 melaninogenica; (B) P. histicola; (C) P. denticola; (D) P. nanceiensis; (E) P. jejuni; (F) P. nigrescens;
- 489 (G) P. salivae; and (H) P. buccae.
- Figure 5. Phenotype comparison of *Prevotella nigrescens* on non-selective anaerobic blood medium
 (top) and polyvitaminic-supplemented chocolate agar (bottom) at (A and D) 3 days; (B and E) 5 days;
- 492 and (C and F) 10 days.
- Figure 6. Phenotype comparison of *Prevotella histicola* on non-selective anaerobic blood medium
 (top) and polyvitaminic-supplemented chocolate agar (bottom) at (A and C) 3 days and (B and D) 5
 days.

496 Tables

- 497 **Table 1.** *Prevotella* spp. prevalence in cystic fibrosis (CF) and chronic obstructive pulmonary disease
- 498 (COPD) according to microbiological culture, real-time PCR, and 16S rRNA gene metataxonomics.

	Prevotella +ve	CF	COPD			
ants	Culture	11/21 (52%)	6/21 (29%)			
Participants	PCR	17/21 (81%)	15/21 (71%)			
	Metataxonomics	15/17 (88%)	16/18 (89%)			
Specimens	Culture	16/36 (44%)	9/32 (28%)			
	PCR	29/36 (81%)	21/32 (66%)			
	Metataxonomics	26/31 (84%)	20/22 (91%)			

500 Table 2. Disc diffusion and antimicrobial resistance gene results for genome-sequenced *Prevotella* isolates from cystic fibrosis (CF) or chronic obstructive

501 pulmonary disease (COPD) respiratory secretions, and antibiotic treatment at time of isolate collection.

	<i>Prevotella</i> sp. [¥]	Antibiotic disc diffusion diameter (mm) by antibiotic class												
Strain ID		Macrolide- lincosamides		Tetra- cyclines	Other			β-lactams					cfxA allele	Antibiotic treatment [‡]
		AZM	CLI	DOX	CHL	MZ	тов	AMC	CAZ	TZP	IPM	MEM		
CF-derived isolate	es						4		4					
SCHI0006.S.13	P. histicola	50	60	24*	42	50	6	70	52	64	60	58	Neg	Nil
SCHI0009.S.5	P. melaninogenica	6 [†]	6^{\dagger}	22*	34	38	6	30	30	50	60	46	Neg	FOF, TOB
SCHI0009.S.6	P. histicola	6†	6 [†]	16*	32	6	6	50	40	48	60	44	Neg	FOF, TOB
SCHI0010.S.3	P. nanceiensis	nt [†]	nt [†]	nt*	nt	nt	nt	nt	nt	nt	nt	nt	cfxA3	CAZ, TOB
SCHI0011.S.12	P. nanceiensis	32	40	14*	34	6	6	20	6	44	56	46	cfxA3	CAZ, TOB
SCHI0011.S.13	P. jejuni	46	48	20*	34	46	6	34	32	52	62	40	Neg	CAZ, TOB
SCHI0018.S.9	P. salivae	nt^\dagger	nt [†]	nt*	nt	nt	nt	nt	nt	nt	nt	nt	cfxA3	CAZ, TZP, TOB
SCHI0021.S.9	P. denticola	6 [†]	6 [†]	24*	34	58	6	24	10	46	54	44	cfxA4	CAZ, TOB
SCHI0027.S.6	P. melaninogenica	26	52	44	32	42	6	24	14	42	54	46	Neg	CAZ, TOB
SCHI0027.S.7	P. histicola	6 [†]	6 [†]	50	34	40	6	14	10	48	50	46	cfxA3	CAZ, TOB
SCHI0027.S.9	P. melaninogenica	42 [†]	34^{\dagger}	40	44	6	6	48	40	52	64	50	cfxA3	CAZ, TOB
SCHI0027.S.11	P. melaninogenica	nt [†]	nt [†]	nt	nt	nt	nt	nt	nt	nt	nt	nt	cfxA3	CAZ, TOB
SCHI0027.S.12	P. denticola	8 [†]	6 [†]	20*	34	44	6	10	6	38	46	38	cfxA3	CAZ, TOB
SCHI0027.S.13	P. melaninogenica	nt [†]	nt [†]	nt	nt	nt	nt	nt	nt	nt	nt	nt	cfxA3	CAZ, TOB
SCHI0027 .S.14	P. denticola	14 [†]	6^{\dagger}	56	42	50	6	14	8	48	48	40	cfxA3	CAZ, TOB
SCHI0028.S.1	P. histicola	18	54	14*	38	40	6	50	32	44	60	26	cfxA2	MEM, TOB
SCHI0028.S.4	P. histicola	20	64	24*	48	44	6	26	34	56	62	40	cfxA2	MEM, TOB
SCHI0028.S.5	P. nigrescens	10 [†]	50^{\dagger}	30*	50	60	6	36	24	50	56	50	cfxA2	MEM, TOB
COPD-derived iso	lates													
SCHI0034.S.5	P. histicola	52	70	64	50	60	6	66	58	66	60	50	Neg	Nil
SCHI0034.S.6	P. histicola	44	60	58	42	50	6	58	50	58	58	50	Neg	Nil
SCHI0034.S.7	P. melaninogenica	40	48	12*	34	38	6	48	20	46	52	54	cfxA3	Nil
SCHI0034.S.8	P. salivae	38	54	20*	36	46	6	50	20	50	54	48	Neg	Nil
SCHI0034.S.9	P. melaninogenica	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	cfxA3	Nil
SCHI0034.S.10	P. histicola	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	Neg	Nil
SCHI0034.S.11	P. salivae	46	50	20*	36	44	6	48	26	48	52	52	Neg	Nil
SCHI0042.S.4	P. denticola	38	46	24*	36	46	6	18	14	44	50	42	cfxA2,	AMX

													cfxA5	
SCHI0042.S.5	P. nanceiensis	30	36	26*	34	6	6	14	12	36	52	52	cfxA3	AMX
SCHI0043.S.1	P. melaninogenica	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	Neg	Nil
SCHI0043.S.2	P. melaninogenica	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	Neg	Nil
SCHI0043.S.3	P. melaninogenica	36	44	54	36	48	6	50	34	50	58	50	Neg	Nil
SCHI0044.S.1	P. melaninogenica	34	56	60	42	48	6	30	24	56	58	52	Neg	Nil
SCHI0047.S.2	P. melaninogenica	40	48	24*	32	48	6	18	12	50	50	46	cfxA2	Nil
SCHI0047.S.3	P. salivae	40	48	24*	32	48	6	18	12	50	50	46	Neg	Nil
SCHI0047.S.4	P. buccae	46	58	54	42	52	6	52	38	58	56	50	Neg	Nil
SCHI0049.S.1	P. melaninogenica	44	58	58	44	50	6	24	20	58	60	52	cfxA3	Nil
LMG 28911 (type strain)	P. melaninogenica	40	54	50	36	46	6	50	50	54	52	38	Unknown	Unknow

502 Abbreviations: AMC, amoxicillin-clavulanate; AMX, amoxicillin; AZM, azithromycin; CAZ, ceftazidime; CHL, chloramphenicol; CLI, clindamycin; DOX,

503 doxycycline; FOF, fosfomycin; IPM, imipenem; MEM, meropenem; MZ, metronidazole; Neg, negative; nt, not tested for antimicrobial sensitivity; TZP,

- 504 piperacillin-tazobactam; TOB, tobramycin
- 505 Dark grey-shaded cells represent definitive antimicrobial resistance (i.e. growth right up to the disc), light grey-shaded cells reflect reduced susceptibility
- 506 (<30mm diameter), and unshaded cells represent probable sensitivity (>30mm diameter)
- [†]Encodes *ermF*, which confers resistance towards erythromycin⁷⁰
- ⁵⁰⁸ [‡]At time of clinical specimen collection from which the isolate was derived
- ⁵⁰⁹ *Encodes *tetQ*, which is associated with decreased susceptibility/resistance towards tetracycline-class antibiotics^{68,70} such as DOX
- 510 [¥]As determined from whole-genome sequence analysis

511 References

512	1. Sze MA, Hogg JC, Sin DD. Bacterial microbiome of lungs in COPD. Int J Chron Obstruct Pulmor	ı Dis
513	2014; 9 : 229-38.	
514 515	2. Fenker DE, McDaniel CT, Panmanee W, et al. A comparison between two pathophysiologically of wet misrobiologically cimilar lung diseases, putting fibracia and observative putmenent diseases. (at	
515	yet microbiologically similar lung diseases: cystic fibrosis and chronic obstructive pulmonary disease. Int a Pulm Med 2018; 5(2).	Respir
517	 Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancer 	2007.
518	370 (9589): 786-96.	2007,
519	4. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. <i>Clin Microbiol Re</i>	ev
520	2002; 15 (2): 194-222.	
521	5. Jacobs DM, Pandit U, Sethi S. Acute exacerbations in chronic obstructive pulmonary disease: sh	ould
522	we use antibiotics and if so, which ones? <i>Curr Opin Infect Dis</i> 2019; 32 (2): 143-51.	
523	6. Larsen JM. The immune response to Prevotella bacteria in chronic inflammatory disease. Immur	iology
524	2017; 151 (4): 363-74.	
525	7. Gilpin DF, Nixon KA, Bull M, et al. Evidence of persistence of <i>Prevotella</i> spp. in the cystic fibrosis	រ lung. J
526	Med Microbiol 2017; 66(6): 825-32.	
527	8. Ditz B, Christenson S, Rossen J, et al. Sputum microbiome profiling in COPD: beyond singular	
528	pathogen detection. <i>Thorax</i> 2020; 75 (4): 338-44.	
529 530	9. Pattison SH, Rogers GB, Crockard M, Elborn JS, Tunney MM. Molecular detection of CF lung	
531	 pathogens: current status and future potential. J Cyst Fibros 2013; 12(3): 194-205. Lee SW, Kuan CS, Wu LS, Weng JT. Metagenome and metatranscriptome profiling of moderate 	and
532	severe COPD sputum in Taiwanese Han males. <i>PLoS One</i> 2016; 11 (7): e0159066.	anu
533	11. Muhlebach MS, Hatch JE, Einarsson GG, et al. Anaerobic bacteria cultured from cystic fibrosis a	irwavs
534	correlate to milder disease: a multisite study. <i>Eur Respir J</i> 2018; 52 (1).	
535	12. Amat S, Lantz H, Munyaka PM, Willing BP. Prevotella in pigs: the positive and negative associat	ions
536	with production and health. <i>Microorganisms</i> 2020; 8 (10).	
537	13. Wybo I, Soetens O, De Bel A, et al. Species identification of clinical <i>Prevotella</i> isolates by matrix	
538	assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2012; 50(4): 1415-8.	
539	14. Tunney MM, Field TR, Moriarty TF, et al. Detection of anaerobic bacteria in high numbers in spur	tum
540	from patients with cystic fibrosis. Am J Respir Crit Care Med 2008; 177(9): 995-1001.	
541	15. Cuthbertson L, Walker AW, Oliver AE, et al. Lung function and microbiota diversity in cystic fibro	SIS.
542	Microbiome 2020; 8(1): 45.	Thorny
543 544	 Han MK, Huang YJ, Lipuma JJ, et al. Significance of the microbiome in obstructive lung disease. 2012; 67(5): 456-63. 	Thorax
545	17. Wang Z, Maschera B, Lea S, et al. Airway host-microbiome interactions in chronic obstructive	
546	pulmonary disease. <i>Respir Res</i> 2019; 20 (1): 113.	
547	18. Mirkovic B, Murray MA, Lavelle GM, et al. The role of short-chain fatty acids, produced by anaero	obic
548	bacteria, in the cystic fibrosis airway. Am J Respir Crit Care Med 2015; 192(11): 1314-24.	
549	19. Field TR, Sibley CD, Parkins MD, Rabin HR, Surette MG. The genus <i>Prevotella</i> in cystic fibrosis	
550	airways. Anaerobe 2010; 16 (4): 337-44.	
551	20. Ulrich M, Beer I, Braitmaier P, et al. Relative contribution of <i>Prevotella intermedia</i> and <i>Pseudomo</i>	onas
552	aeruginosa to lung pathology in airways of patients with cystic fibrosis. Thorax 2010; 65(11): 978-84.	
553	21. Jorth P, Ehsan Z, Rezayat A, et al. Direct lung sampling indicates that established pathogens do	minate
554	early infections in children with cystic fibrosis. <i>Cell Rep</i> 2019; 27 (4): 1190-204.	
555 556	22. Zemanick ET, Wagner BD, Sagel SD, Stevens MJ, Accurso FJ, Harris JK. Reliability of quantitat time PCR for bacterial detection in cystic fibrosis airway specimens. <i>PLoS One</i> 2010; 5 (11): e15101.	ve real-
557	23. O'Neill K, Bradley JM, Johnston E, et al. Reduced bacterial colony count of anaerobic bacteria is	
558	associated with a worsening in lung clearance index and inflammation in cystic fibrosis. <i>PLoS One</i> 2015;	
559	e0126980.	
560	24. Einarsson GG, Zhao J, LiPuma JJ, Downey DG, Tunney MM, Elborn JS. Community analysis ar	d co-
561	occurrence patterns in airway microbial communities during health and disease. ERJ Open Res 2019; 5(3	
562	25. Wang Z, Liu H, Wang F, et al. A refined view of airway microbiome in chronic obstructive pulmon	ary
563	disease at species and strain-levels. Front Microbiol 2020; 11: 1758.	
564	26. Human Microbiome Jumpstart Reference Strains Consortium. A catalog of reference genomes fr	om the
565	human microbiome. <i>Science</i> 2010; 328 (5981): 994-9.	
566	27. Gupta VK, Chaudhari NM, Iskepalli S, Dutta C. Divergences in gene repertoire among the refere	nce
567 568	 Prevotella genomes derived from distinct body sites of human. BMC Genomics 2015; 16: 153. Zhang Y, Zhen M, Zhan Y, Song Y, Zhang Q, Wang J. Population-genomic insights into variation 	in
569	<i>Prevotella intermedia</i> and <i>Prevotella nigrescens</i> isolates and its association with periodontal disease. <i>Fro.</i>	
570	Infect Microbiol 2017; 7: 409.	
571	29. Tett A, Huang KD, Asnicar F, et al. The <i>Prevotella copri</i> complex comprises four distinct clades	
572	underrepresented in Westernized populations. <i>Cell Host Microbe</i> 2019; 26 (5): 666-79.	
573	30. de Lamballerie X, Zandotti C, Vignoli C, Bollet C, de Micco P. A one-step microbial DNA extraction	วท

574 method using "Chelex 100" suitable for gene amplification. *Res Microbiol* 1992; **143**(8): 785-90.

575 31. Triant DA, Whitehead A. Simultaneous extraction of high-guality RNA and DNA from small tissue 576 samples. J Hered 2009: 100(2): 246-50. 577 Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 32 578 1990; **215**(3): 403-10. 579 Klaassen CH, Jeunink MA, Prinsen CF, et al. Quantification of human DNA in feces as a diagnostic test 33. 580 for the presence of colorectal cancer. Clin Chem 2003; 49(7): 1185-7. 581 34. Nadkarni MA, Martin FE, Jacques NA, Hunter N. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology (Reading) 2002; 148(Pt 1): 257-66. 582 583 35. Price EP. Dale JL. Cook JM. et al. Development and validation of Burkholderia pseudomallei-specific 584 real-time PCR assays for clinical, environmental or forensic detection applications. PLoS One 2012; 7(5): 585 e37723. 586 36. Hudzicki J. Kirby-Bauer Disk Diffusion Susceptibility Test Protocol. 2016. 587 https://asm.org/Protocols/Kirby-Bauer-Disk-Diffusion-Susceptibility-Test-Pro (accessed 11Dec20). 588 Bankevich A, Nurk S, Antipov D, et al. SPAdes: a new genome assembly algorithm and its applications 37. 589 to single-cell sequencing. J Comput Biol 2012; 19(5): 455-77. 590 Jolley KA, Bliss CM, Bennett JS, et al. Ribosomal multilocus sequence typing: universal characterization 38 591 of bacteria from domain to strain. Microbiology (Reading) 2012; 158(Pt 4): 1005-15. 592 Larkin MA, Blackshields G, Brown NP, et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007; 39 593 23(21): 2947-8. 594 40. Sarovich DS, Price EP. SPANDx: a genomics pipeline for comparative analysis of large haploid whole 595 genome re-sequencing datasets. BMC Res Notes 2014; 7: 618. 596 Huang W, Li L, Myers JR, Marth GT. ART: a next-generation sequencing read simulator. Bioinformatics 41. 597 2012; 28(4): 593-4. 598 Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. 42 599 Bioinformatics 2014; 30(15): 2114-20. 600 Price EP, Viberg LT, Kidd TJ, Bell SC, Currie BJ, Sarovich DS. Transcriptomic analysis of longitudinal 43 601 Burkholderia pseudomallei infecting the cystic fibrosis lung. Microb Genom 2018; 4(8). 602 Alcock BP, Raphenya AR, Lau TTY, et al. CARD 2020: antibiotic resistome surveillance with the 44. 603 comprehensive antibiotic resistance database. Nucleic Acids Res 2020; 48(D1): D517-D25. 604 Silva VL, Carvalho MA, Nicoli JR, Farias LM. Aerotolerance of human clinical isolates of Prevotella spp. 45. 605 J Appl Microbiol 2003; 94(4): 701-7. 606 Aziz A, Currie BJ, Mayo M, Sarovich DS, Price EP. Comparative genomics confirms a rare melioidosis 46. 607 human-to-human transmission event and reveals incorrect phylogenomic reconstruction due to polyclonality. 608 Microb Genom 2020: 6(2). 609 47. Xie Y, Chen J, He J, et al. Antimicrobial resistance and prevalence of resistance genes of obligate 610 anaerobes isolated from periodontal abscesses. J Periodontol 2014; 85(2): 327-34. 611 Goddard AF, Staudinger BJ, Dowd SE, et al. Direct sampling of cystic fibrosis lungs indicates that DNA-48 612 based analyses of upper-airway specimens can misrepresent lung microbiota. Proc Natl Acad Sci U S A 2012; 613 **109**(34): 13769-74. 614 49. Pragman AA, Lyu T, Baller JA, et al. The lung tissue microbiota of mild and moderate chronic 615 obstructive pulmonary disease. Microbiome 2018; 6(1): 7. 616 Dickson RP, Erb-Downward JR, Freeman CM, et al. Bacterial topography of the healthy human lower 50 617 respiratory tract. mBio 2017; 8(1). Bassis CM. Erb-Downward JR. Dickson RP, et al. Analysis of the upper respiratory tract microbiotas as 618 51. 619 the source of the lung and gastric microbiotas in healthy individuals. mBio 2015; 6(2): e00037. 620 Larsen JM, Steen-Jensen DB, Laursen JM, et al. Divergent pro-inflammatory profile of human dendritic 52. 621 cells in response to commensal and pathogenic bacteria associated with the airway microbiota. PLoS One 2012; 622 7(2): e31976. 623 Hedberg ME, Israelsson A, Moore ERB, et al. Prevotella jejuni sp. nov., isolated from the small intestine 53. 624 of a child with coeliac disease. Int J Syst Evol Microbiol 2013; 63(Pt 11): 4218-23. 625 Enaud R, Prevel R, Ciarlo E, et al. The gut-lung axis in health and respiratory diseases: a place for inter-54 626 organ and inter-kingdom crosstalks. Front Cell Infect Microbiol 2020; 10: 9. 627 Bertelsen A, Elborn SJ, Schock BC. Toll like Receptor signalling by Prevotella histicola activates 55. 628 alternative NF-kappaB signalling in cystic fibrosis bronchial epithelial cells compared to P. aeruginosa. PLoS One 629 2020; 15(10): e0235803. 630 Di Lorenzo F, Silipo A, Matier T, et al. Prevotella denticola lipopolysaccharide from a cystic fibrosis 56. 631 isolate possesses a unique chemical structure. European J Org Chem 2016; 9: 1732-8. 632 Yanagisawa M, Kuriyama T, Williams DW, Nakagawa K, Karasawa T. Proteinase activity of Prevotella 57. 633 species associated with oral purulent infection. Curr Microbiol 2006; 52(5): 375-8. 634 Alauzet C, Marchandin H, Lozniewski A. New insights into Prevotella diversity and medical microbiology. 58 635 Future Microbiol 2010; 5(11): 1695-718. 636 59. Sherrard LJ, Graham KA, McGrath SJ, et al. Antibiotic resistance in Prevotella species isolated from 637 patients with cystic fibrosis. J Antimicrob Chemother 2013; 68(10): 2369-74. 638 Brill SE, Law M, El-Emir E, et al. Effects of different antibiotic classes on airway bacteria in stable COPD 60. 639 using culture and molecular techniques: a randomised controlled trial. Thorax 2015; 70(10): 930-8. 640 Veloo ACM, Baas WH, Haan FJ, Coco J, Rossen JW. Prevalence of antimicrobial resistance genes in 61. 641 Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect 2019; 25(9): 1156 e9- e13.

642 Sherrard LJ, Tunney MM, Elborn JS. Antimicrobial resistance in the respiratory microbiota of people with 62. 643 cystic fibrosis. Lancet 2014; 384(9944): 703-13. 644 Hahn A, Burrell A, Fanous H, et al. Antibiotic multidrug resistance in the cystic fibrosis airway 63. 645 microbiome is associated with decreased diversity. Heliyon 2018; 4(9): e00795. 646 Nelson MT, Wolter DJ, Eng A, et al. Maintenance tobramycin primarily affects untargeted bacteria in the 64. 647 CF sputum microbiome. Thorax 2020; 75(9): 780-90. 648 Bittar F, Richet H, Dubus JC, et al. Molecular detection of multiple emerging pathogens in sputa from 65. 649 cystic fibrosis patients. PLoS One 2008; 3(8): e2908. 650 Shakil S, Khan R, Zarrilli R, Khan AU. Aminoglycosides versus bacteria--a description of the action, 66. 651 resistance mechanism, and nosocomial battleground. J Biomed Sci 2008; 15(1): 5-14. 652 Thornton CS, Surette MG. Potential contributions of anaerobes in cystic fibrosis airways. J Clin Microbiol 67. 653 2021; 59(3) 654 68 Sherrard LJ, Schaible B, Graham KA, et al. Mechanisms of reduced susceptibility and genotypic 655 prediction of antibiotic resistance in *Prevotella* isolated from cystic fibrosis (CF) and non-CF patients. J 656 Antimicrob Chemother 2014; 69(10): 2690-8. 657 Parameswaran GI, Sethi S. Long-term macrolide therapy in chronic obstructive pulmonary disease. 69 658 CMAJ 2014; 186(15): 1148-52. 659 Arzese AR. Tomasetia L. Botta GA. Detection of tetQ and ermF antibiotic resistance genes in Prevotella 70. 660 and Porphyromonas isolates from clinical specimens and resident microbiota of humans. J Antimicrob 661 Chemother 2000; 45(5): 577-82. 662 Fernández-Canigia L, Cejas D, Gutkind G, Radice M. Detection and genetic characterization of beta-71. 663 lactamases in Prevotella intermedia and Prevotella nigrescens isolated from oral cavity infections and 664 peritonsillar abscesses. Anaerobe 2015; 33: 8-13. 665 72 Sherrard LJ, McGrath SJ, McIlreavey L, et al. Production of extended-spectrum β-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota. Int J 666 667 Antimicrob Agents 2016; 47(2): 140-5. 668 Jolivet-Gougeon A, Tamanai-Shacoori Z, Desbordes L, Burggraeve N, Cormier M, Bonnaure-Mallet M. 73. Genetic analysis of an ambler class A extended-spectrum beta-lactamase from Capnocytophaga ochracea. J 669

670 Clin Microbiol 2004; 42(2): 888-90.

67174.Alauzet C, Mory F, Teyssier C, et al. Metronidazole resistance in *Prevotella* spp. and description of a672new nim gene in *Prevotella baroniae*. Antimicrob Agents Chemother 2010; **54**(1): 60-4.


Veloo ACM, Chlebowicz M, Winter HLJ, Bathoorn D, Rossen JWA. Three metronidazole-resistant *Prevotella bivia* strains harbour a mobile element, encoding a novel *nim* gene, *nimK*, and an efflux small MDR
transporter. J Antimicrob Chemother 2018; **73**(10): 2687-90.

Allison HE, Hillman JD. Cloning and characterization of a *Prevotella melaninogenica* hemolysin. *Infect Immun* 1997; 65(7): 2765-71.


T7. Zhou X, Li Y. Subgingival microbes: from healthy microflora to disease. Atlas of Oral Microbiology:
 Elsevier; 2015.


Finegold SM. Anaerobic Gram-negative bacilli (Chapter 20). In: Baron S, ed. Medical Microbiology (4th
 edition). Galveston, TX: University of Texas Medical Branch at Galveston; 1996.

Amplification



Standard Curve





CI=0.81

CI=0.82

Prevotella melaninogenica

